PT  - JOURNAL ARTICLE
AU  - Young, Ruth
AU  - Ssekasanvu, Joseph
AU  - Kagaayi, Joseph
AU  - Ssekubugu, Robert
AU  - Kigozi, Godfrey
AU  - Reynolds, Steven J.
AU  - Wawer, Maria J.
AU  - Nonyane, Bareng A.S.
AU  - Chang, Larry W.
AU  - Kennedy, Caitlin E.
AU  - Paina, Ligia
AU  - Anglewicz, Philip A.
AU  - Quinn, Thomas C.
AU  - Serwadda, David
AU  - Nalugoda, Fred
AU  - Grabowski, M. Kate
TI  - HIV and viremia prevalence in non-migrating members of migrant households in Rakai region, Uganda: A cross-sectional population-based study
AID  - 10.1101/2023.12.08.23299745
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.08.23299745
4099  - http://medrxiv.org/content/early/2023/12/10/2023.12.08.23299745.short
4100  - http://medrxiv.org/content/early/2023/12/10/2023.12.08.23299745.full
AB  - Introduction In sub-Saharan Africa, migrants are more likely to be HIV seropositive and viremic than non-migrants. However, little is known about HIV prevalence and viremia in non-migrants living in households with in- or out-migration events. We compared HIV outcomes in non-migrating persons in households with and without migration events using data from the Rakai Community Cohort Study (RCCS), an open population-based cohort in UgandaMethods We analyzed RCCS survey data from one survey round collected between August 2016 and May 2018 from non-migrating participants aged 15–49. Migrant households were classified as those reporting ≥1 member moving into or out of the household since the prior survey. A validated rapid test algorithm determined HIV serostatus. HIV viremia was defined as >1,000 copies/mL. Modified Poisson regression was used to estimate associations between household migration and HIV outcomes, with results reported as adjusted prevalence ratios (adjPR) with 95% confidence intervals (95%CI). Analyses were stratified by gender, direction of migration (into/out of the household), and relationship between non-migrants and migrants (e.g., spouse).Results There were 14,599 non-migrants (7,654, 52% women) identified in 9,299 households. 4,415 (30%) lived in a household with ≥1 recent migrant; of these, 972(22%) had migrant spouses, 1,102(25%) migrant children, and 875(20%) migrant siblings. Overall, HIV prevalence and viremia did not differ between non-migrants in migrant and non-migrant households. However, in stratified analyses, non-migrant women with migrant spouses were significantly more likely to be HIV seropositive compared to non-migrant women with non-migrant spouses (adjPR:1.44, 95%CI:1.21-1.71). Conversely, non-migrant mothers living with HIV who had migrant children were less likely to be viremic (adjPR:0.34, 95%CI:0.13-0.86). Among non-migrant men living with HIV, spousal migration was associated with a non-significant increased risk of viremia (adjPR:1.37, 95%CI:0.94-1.99). Associations did not typically differ for migration into or out of the household.Conclusions Household migration was associated with HIV outcomes for certain non-migrants, suggesting that the context of household migration influences the observed association with HIV outcomes. In particular, non-migrating women with migrating spouses were more likely to have substantially higher HIV burden. Non-migrants with migrant spouses may benefit from additional support when accessing HIV services.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Institute of Allergy and Infectious Diseases (grant numbers R01AI114438, R01AI110324, R01AI123002, R01AI128779), the National Institute of Mental Health (grant number R01MH107275, R01MH105313, R01MH099733), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant number R01HD091003), the Division of Intramural Research of the National Institute for Allergy and Infectious Diseases, and the President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention (grant number NU2GGH000817). RY was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under award number [1F31HD102287]. We thank the personnel at the Office of Cyberinfrastructure and Computational Biology at the National Institute of Allergy and Infectious Diseases for data management support. Additionally, we thank the cohort participants and many staff and investigators who made this study possible. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Research Ethics Committee of the Ugandan Virus Research Institute (GC/127/19/11/137), Uganda National Council for Science and Technology (HS 540), Johns Hopkins School of Medicine IRB (IRB00217467), and Western Institutional Review Board, Olympia Washington (Protocol #20031318) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes95%CI95% confidence intervaladjPRAdjusted prevalence ratioARTAntiretroviral therapyHHHouseholdHIVHuman immunodeficiency virusmLMilliliterPCRPolymerase chain reactionPRCrude prevalence ratioRCCSRakai Community Cohort StudySSSecondary schoolyrsyears